

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Salmon Sean</u> _____ (Last) (First) (Middle) 710 MEDTRONIC PARKWAY LC300 _____ (Street) MINNEAPOLIS MN 55432 _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 11/01/2019	3. Issuer Name and Ticker or Trading Symbol <u>Medtronic plc [ MDT ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>EVP &amp; Group President Diabetes</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	25,409 <sup>(1)</sup>	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	10/28/2020 <sup>(2)</sup>	10/28/2029	Ordinary Shares	14,716	106.22	D	
Stock Option (Right to Buy)	07/30/2013 <sup>(2)</sup>	07/30/2022	Ordinary Shares	21,129	38.81	D	
Stock Option (Right to Buy)	07/30/2013 <sup>(2)</sup>	07/30/2022	Ordinary Shares	2,577	38.81	D	
Stock Option (Right to Buy)	07/29/2014 <sup>(2)</sup>	07/29/2023	Ordinary Shares	14,823	55.32	D	
Stock Option (Right to Buy)	07/29/2014 <sup>(2)</sup>	07/29/2023	Ordinary Shares	1,808	55.32	D	
Stock Option (Right to Buy)	07/28/2015 <sup>(2)</sup>	07/28/2024	Ordinary Shares	13,066	62.76	D	
Stock Option (Right to Buy)	07/28/2015 <sup>(2)</sup>	07/28/2024	Ordinary Shares	1,594	62.76	D	
Stock Option (Right to Buy)	08/03/2016 <sup>(2)</sup>	08/03/2025	Ordinary Shares	17,095	78	D	
Stock Option (Right to Buy)	08/03/2016 <sup>(2)</sup>	08/03/2025	Ordinary Shares	1,283	78	D	
Stock Option (Right to Buy)	08/01/2017 <sup>(2)</sup>	08/01/2026	Ordinary Shares	15,142	88.06	D	
Stock Option (Right to Buy)	08/01/2017 <sup>(2)</sup>	08/01/2026	Ordinary Shares	1,136	88.06	D	
Stock Option (Right to Buy)	07/31/2018 <sup>(2)</sup>	07/31/2027	Ordinary Shares	27,788	83.97	D	
Stock Option (Right to Buy)	07/31/2018 <sup>(2)</sup>	07/31/2027	Ordinary Shares	1,191	83.97	D	
Stock Option (Right to Buy)	07/30/2019 <sup>(2)</sup>	07/30/2028	Ordinary Shares	25,983	89.08	D	
Stock Option (Right to Buy)	07/30/2019 <sup>(2)</sup>	07/30/2028	Ordinary Shares	1,695	89.08	D	
Stock Option (Right to Buy)	07/29/2020 <sup>(2)</sup>	07/29/2029	Ordinary Shares	21,532	103.26	D	
Stock Option (Right to Buy)	07/29/2020 <sup>(2)</sup>	07/29/2029	Ordinary Shares	1,615	103.26	D	
Stock Option (Right to Buy)	04/30/2013 <sup>(2)</sup>	04/30/2022	Ordinary Shares	4,713	38.2	D	
Stock Option (Right to Buy)	06/29/2018 <sup>(3)</sup>	01/27/2025	Ordinary Shares	16,035	74.84	D	

**Explanation of Responses:**

1. Includes grants of restricted stock units which vest on the listed date and for the listed number of shares if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth measured over the three most recently completed fiscal years exceeds a 3% cumulative compound annual growth rate (as determined by the Compensation Committee): (i) 7,300 restricted stock units that vest on 7/31/2020; (ii) 4,422 restricted stock units that vest on 7/30/2021; and (iii) 5,474 restricted stock units that vest on 7/29/2022.
2. These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of the grant.
3. This option became exercisable on June 29, 2018, subject to Medtronic plc's achievement of a pre-specified cash Earnings Per Share Growth Rate for fiscal years 2016 through 2018.

/s/ Perry F. Sekus, attorney-in-  
fact 11/07/2019

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY

Know all by these presents, that the undersigned, director or officer, or both, of Medtronic plc, hereby constitutes and appoints each of Bradley E. Lerman, Martha Ha, Thomas L. Osteraas, Perry F. Sekus and Anne M. Ziebell signing singly, the undersigned's true and lawful attorney-in-fact to:

(1) prepare, execute in the undersigned's and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain or update passphrase, codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 and any rule or regulation of the SEC;

(2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Medtronic plc (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms 3, 4, 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney shall supersede any and all existing Powers of Attorney with respect to the subject matter hereof.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 23 day of October 2019.

/s/ Sean Salmon

Sean Salmon